The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Official Title: A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Study ID: NCT01497041
Brief Summary: 1. Goals The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with stage IIIB/IV non-adenocarcinoma, non-small cell lung cancer (NSCLC) as second-line treatment Secondary goals are to: evaluate the treatment-related toxicities of this combination, investigate progression-free survival (PFS) and overall survival (OS) in this population 2. Design The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon two-stage testing procedure
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Soonchunhyang University Cheonan Hospital, Cheonan, , Korea, Republic of
Chungbuk National University Hospital, Cheongju, , Korea, Republic of
Chungnam National University Hospital, Daejeon, , Korea, Republic of
The Catholic University of Korea Daejeon ST. Mary's Hospital, Daejeon, , Korea, Republic of
Chonbuk National University Hospital, Jeonju, , Korea, Republic of
Name: Sang Byung Bae, M.D.
Affiliation: Soonchunhyang University Hospital
Role: PRINCIPAL_INVESTIGATOR